The therapeutic landscape of MM has advanced with the advent of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, histone deacetylase inhibitors, selective inhibitors of nuclear export, NK cell–based therapies, and anti-BCMA immunotherapies. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.